Abstract:Non-Alcoholic Fatty Liver Disease (NAFLD) is often a hepatic complication of obese, hyperlipidemia, diabetes and metabolic syndrome, and affects more than one third of general population in the US and 15% in China. It covers a spectrum of fat accumulation-associated disorders, ranging from simple fatty liver, Nonalcoholic Steatohepatitis (NASH), and End-Stage Liver Disease (ESLD). Approximately, one fifth of NAFLD patients will develop NASH, which may further progress to ESLD with various complications. Hepatocellular Carcinoma (HCC) may occur in all stages of NAFLD, and accounts for an increased incidence of HCC in the US. Despite of pandemic prevalence of NAFLD/NASH, etiology-specific treatment has not been available yet, nor is its pathogenesis fully understood. The multi-factorial feature of this disorder dictates the variance in susceptibility, possibility of disease progression and responses to therapeutics, and requires that therapeutics targeting more than single pathway should be developed, and personalized treatment implemented. To reach such goals, the delineation of Endoplasmic Reticulum (ER) stress and lipophagy, two pathophysiologic responses in addition to known pathologic alterations, such as lipotoxicity, oxidant stress, insulin resistance, would allow revealing the molecular basis for NASH initiation and progression, and point to a right direction for new therapeutic development. The present review aims to cover the current understanding of how ER stress and autophagy take a part in the initiation and progression of NASH, and what therapeutic hints exist in deep insights into these two pathophysiologic responses. The ultimate goal is to develop more effective strategies for NASH intervention.

Advances of Research on Lipotoxicity and Nonalcoholic Fatty Liver Disease

Research Progress on Lipophagy-Mediated Exercise Intervention in Non-Alcoholic Fatty Liver Disease

Research Progress on the Mechanism of Traditional Chinese Medicine in the Treatment of Non-Alcoholic Fatty Liver Disease Based on Oxidative Stress

Potential Therapeies for Nonalcoholic Fatty Liver Disease

Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease

Progress of potential drugs in non-alcohol fatty liver disease

Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Current Advances in the Regulatory Effects of Bioactive Compounds from Dietary Resources on Nonalcoholic Fatty Liver Disease: Role of Autophagy

Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease

Molecular Mechanisms and Mediators of Hepatotoxicity Resulting from an Excess of Lipids and Non-Alcoholic Fatty Liver Disease

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Roles of Abnormal Lipid Metabolism in Pathogenesis of Non-Alcoholic Fatty Liver Disease

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis

Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease

Targeting cell death in NAFLD: mechanisms and targeted therapies

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective.

Research Advances in Extrahepatic Diseases Associated with Nonalcoholic Fatty Liver Disease